TOKYO--(BUSINESS WIRE)--GNI Ltd, a leading biopharmaceutical company in Asia, has announced that its China based affiliate Shanghai Genomics has expanded sales of Gu-BangTM, a new type of synthetic bone biomaterial, after winning several hospital supply contracts in Beijing, Shanghai and Guandong province. Shanghai Genomics received a Product Registration Certificate from the Chinese State Food and Drug Administration (SFDA) to market Gu-BangTM earlier this year.
